Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Gastrointestinal carcinoid tumor
Trial Status:  Active
Results 1-25 of 120 for your search:
Start Over
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 170/11, NCT01552291
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
Nutritional Supplementation in Patients With no Signs of Malnutrition
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Nutri01, NCT01894828
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A-97-52030-270, NCT02075606
The Laparotomy Study
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Lap2014NMB, 2014-001155-22, NCT02140593
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PRODIGE31, NCT02288377
An Intervention to Improve Outcomes in Patients With Advanced Cancer
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 0909005722, R01NR011872, NCT01272024
Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AAA-III-01, 2011-005049-11, NCT01578239
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: LOTUS, 2011-006097-76, NCT01755182
Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CHU-0137, 2011-A00911-40, NCT01775449
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IJBMNLUMEN, 2012-003666-41, NCT01842165
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB12004, NCT02009423
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Phase: Phase III
Type: Diagnostic, Health services research
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 15-999, NCT02375464
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: SP-24513/DX-FLT-002, NCT01065805
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201404101, NCT01790035
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSC_apceth_101/1, NCT02008539
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 092/11, NCT02078843
Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 271296-HMO-CTIL, NCT00149006
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
Start Over